OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Cancer is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	190
Advancing radiomics from contrast-enhanced mammography in breast cancer	174
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours	149
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	145
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	138
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis	114
Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways	112
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	110
Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort	109
Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment	102
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	99
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	96
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	96
Metabolic adaptations in prostate cancer	96
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	93
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	92
Correction: Wnt/ERK/CDK4/6 activation in the partial EMT state coordinates mammary cancer stemness with self-renewal and inhibition of differentiation	90
Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients	90
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	90
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	89
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	88
Navigating therapeutic strategies: HPV classification in head and neck cancer	87
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	84
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	83
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	79

Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	77
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	77
Metastasis-associated fibroblasts in peritoneal surface malignancies	76
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	76
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles	74
Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US	72
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	71
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	70
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	70
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analy	67
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	67
Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians	67
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	66
Genomic ALK alterations in primary and relapsed neuroblastoma	65
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	65
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	65
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	64
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	63
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	62
Identification of increased dedifferentiation along the Prom1+ cancer cells in Müllerian adenosarcoma with sarcomatous overgrowth	62
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	62
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme	61
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	59
Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma	59
Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors	59
Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner	59
The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England	58
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer	56
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II st	56
Progress and priorities in reducing the time to cancer diagnosis	55